Over the last decade, the breakneck pace of innovation has brought us life-saving treatments and cures for rare diseases, cancer and hepatitis C, among others. Despite these advancements improving the way we treat complex and often debilitating conditions, medicine prices have been growing at the slowest rate in years.
But while prices for brand medicines have remained stable for the health care system, patients have increasingly been facing higher costs at the pharmacy counter. Furthermore, recent proposed changes to Medicare Part B threaten to restrict access to medicines for one of our most vulnerable populations, seniors.
These were just some of the pressing issues discussed by a group of leading health care voices brought together by PhRMA for a panel at the Wall Street Journal’s 2019 Health Forum that was moderated by former U.S. Representative Erik Paulsen (R-MN) and featured PhRMA president and CEO Stephen J. Ubl, JDRF’s senior vice president of Advocacy and Policy Cynthia Rice and associate professor at Boston University’s Quelstrom School of Business Rena Conti.